Ticker

Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting fundamental epigenetic and metabolic drivers of cancer, today announced new in vitro data…

Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms. MIAMI, FLORIDA / ACCESS Newswire / February 5, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule…

Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) is expected to be issuing its results before the market opens on Tuesday, February 3rd. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported

electroCore (NASDAQ: ECOR - Get Free Report) and Telomir Pharmaceuticals (NASDAQ: TELO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Earnings and Valuation This table compares electroCore and

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire / January 5, 2026 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of…